$GOSS
Gossamer Bio, Inc. Stock $goss

$goss Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000172811720000009 Filed on November 10, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.88M	$11.45M	$9.840M
YoY Change	37.01%	16.36%	-56.8%
% of Gross Profit
Research & Development	$38.91M	$41.85M	$40.15M
YoY Change	-8.66%	4.23%	112.91%
% of Gross Profit
Depreciation & Amortization	$370.0K	$360.0K	$260.0K
YoY Change	27.59%	38.46%	116.67%
% of Gross Profit
Operating Expenses	$54.79M	$53.57M	$49.99M
YoY Change	1.11%	7.17%	-0.08%
Operating Profit		-$53.57M	-$49.99M
YoY Change		7.17%	-0.08%
Interest Expense	-$3.500M	$4.715M
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$1.020M	-$4.243M	$1.486M
YoY Change	-193.58%	-385.53%
Pretax Income	-$64.60M	-$57.81M	-$48.50M
YoY Change	18.1%	19.2%	-1.82%
Income Tax
% Of Pretax Income
Net Earnings	-$64.60M	-$57.81M	-$48.50M
YoY Change	18.1%	19.2%	-1.84%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.80
Diluted Earnings Per Share	-$881.9K	-$0.80	-$798.2K
COMMON SHARES
Basic Shares Outstanding	75.93M shares	72.25M shares	65.93M
Diluted Shares Outstanding		72.25M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$512.6M	$555.4M	$446.5M
YoY Change	27.58%	24.39%	74.14%
Cash & Equivalents	$486.1M	$462.0M	$130.7M
Short-Term Investments	$26.60M	$93.40M	$315.8M
Other Short-Term Assets	$9.700M	$10.80M	$5.900M
YoY Change	29.33%	83.05%	210.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$522.3M	$566.2M	$452.4M
YoY Change	27.61%	25.16%	75.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.534M	$5.717M	$5.133M
YoY Change	2.01%	11.38%	71.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.027M	$861.0K	$1.387M
YoY Change	-34.12%	-37.92%	73.38%
Total Long-Term Assets	$17.11M	$17.97M	$17.38M
YoY Change	-1.02%	3.41%	357.37%
TOTAL ASSETS
Total Short-Term Assets	$522.3M	$566.2M	$452.4M
Total Long-Term Assets	$17.11M	$17.97M	$17.38M
Total Assets	$539.4M	$584.2M	$469.8M
YoY Change	26.45%	24.36%	79.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.508M	$865.0K	$2.555M
YoY Change	685.36%	-66.14%	-29.03%
Accrued Expenses	$20.71M	$19.50M	$11.44M
YoY Change	23.95%	70.44%	1.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$38.65M	$32.61M	$33.17M
YoY Change	4.68%	-1.69%	122.61%
LONG-TERM LIABILITIES
Long-Term Debt	$28.74M	$28.67M	$28.37M
YoY Change	1.0%	1.04%
Other Long-Term Liabilities	$7.700M	$8.600M	$9.300M
YoY Change	-11.49%	-7.53%	1228.57%
Total Long-Term Liabilities	$28.74M	$28.67M	$28.37M
YoY Change	1.0%	1.04%	3952.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.65M	$32.61M	$33.17M
Total Long-Term Liabilities	$28.74M	$28.67M	$28.37M
Total Liabilities	$218.7M	$212.1M	$70.88M
YoY Change	195.13%	199.2%	354.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$577.5M	-$512.9M	-$279.5M
YoY Change	72.8%	83.52%
Common Stock	$897.6M	$884.7M	$678.0M
YoY Change	30.77%	30.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$320.7M	$372.1M	$398.9M
YoY Change
Total Liabilities & Shareholders Equity	$539.4M	$584.2M	$469.8M
YoY Change	26.45%	24.36%	79.16%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$64.60M	-$57.81M	-$48.50M
YoY Change	18.1%	19.2%	-1.84%
Depreciation, Depletion And Amortization	$370.0K	$360.0K	$260.0K
YoY Change	27.59%	38.46%	116.67%
Cash From Operating Activities	-$36.74M	-$44.93M	-$36.11M
YoY Change	-16.76%	24.43%	132.82%
INVESTING ACTIVITIES
Capital Expenditures	-$250.0K	-$300.0K	-$710.0K
YoY Change	-52.83%	-57.75%	-58.72%
Acquisitions
YoY Change
Other Investing Activities	$61.35M	$20.26M	$18.66M
YoY Change	29.27%	8.57%	-118.05%
Cash From Investing Activities	$61.10M	$19.96M	$17.95M
YoY Change	30.17%	11.2%	-117.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	250.0K	890.0K	370.0K
YoY Change	-83.55%	140.54%	-99.84%
NET CHANGE
Cash From Operating Activities	-36.74M	-44.93M	-36.11M
Cash From Investing Activities	61.10M	19.96M	17.95M
Cash From Financing Activities	250.0K	890.0K	370.0K
Net Change In Cash	24.61M	-24.08M	-17.79M
YoY Change	469.68%	35.36%	-116.33%
FREE CASH FLOW
Cash From Operating Activities	-$36.74M	-$44.93M	-$36.11M
Capital Expenditures	-$250.0K	-$300.0K	-$710.0K
Free Cash Flow	-$36.49M	-$44.63M	-$35.40M
YoY Change	-16.33%	26.07%	156.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001728117
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38796
	dei	Entity Registrant Name EntityRegistrantName	GOSSAMER BIO, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5461709
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3013 Science Park Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	684-1300
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	GOSS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75927877	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	461956000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	135089000	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	93422000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	266740000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10828000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7488000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	566206000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	409317000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5717000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5425000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11394000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10303000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	861000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1559000	USD
CY2020Q3	us-gaap	Assets Assets	584178000	USD
CY2019Q4	us-gaap	Assets Assets	426604000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	865000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	956000	USD
CY2020Q3	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	12239000	USD
CY2019Q4	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	19258000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19503000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16709000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	32607000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36923000	USD
CY2020Q3	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	142158000	USD
CY2019Q4	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	0	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28665000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28459000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8647000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8737000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	212077000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	74119000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75907527	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72475912	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66284003	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61635477	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	884677000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	686390000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-512926000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-334170000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	342000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	258000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	372101000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	352485000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	584178000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	426604000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	40148000	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	41846000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	121944000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	100807000	USD
CY2020Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	275000	USD
CY2019Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	18080000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2000000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11448000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9838000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33851000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27544000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	53569000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	49986000	USD
	us-gaap	Operating Expenses OperatingExpenses	173875000	USD
	us-gaap	Operating Expenses OperatingExpenses	130351000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-53569000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-49986000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-173875000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-130351000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4243000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1486000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4881000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4742000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-57812000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-48500000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-178756000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-125609000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	68000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	59000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-293000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-168000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	25000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	389000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-225000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-168000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	84000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	389000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58037000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48668000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-178672000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125220000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.67
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.39
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72245897	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60755872	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66931512	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52535569	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	352485000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8244000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	556000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-54074000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-763000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	306463000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	117094000	USD
CY2020Q2	goss	Equity Component Of Convertible Note Issuance EquityComponentOfConvertibleNoteIssuance	53635000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	109000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	139000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8900000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-66870000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1072000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	420324000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8923000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	744000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	16000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-57812000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-225000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	372101000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-120069000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	291344000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	338367000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3089000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-32611000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	140000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	480260000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	86000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5140000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	39000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-44498000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	417000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	441444000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	369000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5728000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-48500000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-168000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	398873000	USD
	us-gaap	Profit Loss ProfitLoss	-178756000	USD
	us-gaap	Profit Loss ProfitLoss	-125609000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1044000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	625000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	26067000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13957000	USD
	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	18080000	USD
	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	2000000	USD
	goss	Amortization Of Operating Lease Right Of Use Assets AmortizationOfOperatingLeaseRightOfUseAssets	2015000	USD
	goss	Amortization Of Operating Lease Right Of Use Assets AmortizationOfOperatingLeaseRightOfUseAssets	1615000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2294000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	148000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-24000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2296000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	256000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3340000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2807000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-698000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2886000	USD
	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	1294000	USD
	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	1566000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	333000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2768000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-760000	USD
	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-7019000	USD
	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	8518000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1959000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2263000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-139624000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100694000	USD
	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	18080000	USD
	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	2000000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	108969000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	399393000	USD
	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	199029000	USD
	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	205750000	USD
	goss	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	83515000	USD
	goss	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	4004000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1253000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2438000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	154242000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-194077000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117110000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	291311000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	193596000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1778000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	28222000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	285000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	527000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	312291000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	320060000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-42000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	326909000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	25289000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135089000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105419000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	461956000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130708000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1911000	USD
	us-gaap	Interest Paid Net InterestPaidNet	854000	USD
	goss	Right Of Use Assets Obtained In Exchange For Lease Liabilities RightOfUseAssetsObtainedInExchangeForLeaseLiabilities	3106000	USD
	goss	Right Of Use Assets Obtained In Exchange For Lease Liabilities RightOfUseAssetsObtainedInExchangeForLeaseLiabilities	12458000	USD
	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	25000	USD
	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	510000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	83000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	127000	USD
	goss	Noncash Financing And Investing Conversions Of Convertible Preferred Stock To Common Stock NoncashFinancingAndInvestingConversionsOfConvertiblePreferredStockToCommonStock	0	USD
	goss	Noncash Financing And Investing Conversions Of Convertible Preferred Stock To Common Stock NoncashFinancingAndInvestingConversionsOfConvertiblePreferredStockToCommonStock	338367000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-512900000	USD
	goss	Funds Raised Through Preferred Equity Financing Convertible Note Financings And Completed Initial Public Offering FundsRaisedThroughPreferredEquityFinancingConvertibleNoteFinancingsAndCompletedInitialPublicOffering	942000000.0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the allocation of the 2027 Notes into liability and equity components, accrued research and development expenses, the valuation of preferred and common stock, the valuation of stock options and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7975000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6639000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2258000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1214000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5717000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5425000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8623000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9282000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3548000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2354000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2581000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2347000	USD
CY2020Q3	us-gaap	Interest Payable Current InterestPayableCurrent	3864000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	612000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1126000	USD
CY2020Q3	goss	Accrued In Process Research And Development AccruedInProcessResearchAndDevelopment	275000	USD
CY2019Q4	goss	Accrued In Process Research And Development AccruedInProcessResearchAndDevelopment	1600000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19503000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16709000	USD
CY2019Q4	us-gaap	Fair Value Equity Level1 To Level2 Transfers Amount FairValueEquityLevel1ToLevel2TransfersAmount	0	USD
CY2020Q3	us-gaap	Fair Value Equity Level1 To Level2 Transfers Amount FairValueEquityLevel1ToLevel2TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Equity Level2 To Level1 Transfers Amount FairValueEquityLevel2ToLevel1TransfersAmount	0	USD
CY2020Q3	us-gaap	Fair Value Equity Level2 To Level1 Transfers Amount FairValueEquityLevel2ToLevel1TransfersAmount	0	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	93120000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	302000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	93422000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	79582000	USD
CY2020Q3	goss	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	13840000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	93422000	USD
CY2020Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2018Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	20000000.0	USD
CY2020Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	275000	USD
CY2019Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	18080000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2000000	USD
	goss	Common Stock Voting Rights Number Of Votes Per Share CommonStockVotingRightsNumberOfVotesPerShare	1	vote
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9433963	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.25
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117100000	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3434613	shares
CY2019	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	4648526	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8538060	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.67
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	35385000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2540122	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.02
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	76275	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	735012	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13.61
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10266895	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.83
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19221000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3274782	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	12.57
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	10026000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.96
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8923000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5728000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26067000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13957000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1007000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2577000	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	16000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	54000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	1023000	USD
	us-gaap	Lease Cost LeaseCost	2631000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2600000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1043000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4273000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3579000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2063000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2123000	USD
CY2020Q3	goss	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	387000	USD
CY2020Q3	goss	Lessee Operating Lease Liability Payments Due After Year Six LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix	397000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13865000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1670000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	12195000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3548000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8647000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	12195000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000.0	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2900000	USD

Files In Submission

Name	View Source	Status
0001728117-20-000009-index-headers.html	Edgar Link	pending
0001728117-20-000009-index.html	Edgar Link	pending
0001728117-20-000009.txt	Edgar Link	pending
0001728117-20-000009-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
goss-20200930.htm	Edgar Link	pending
goss-20200930.xsd	Edgar Link	pending
goss-20200930xxexx311.htm	Edgar Link	pending
goss-20200930xxexx312.htm	Edgar Link	pending
goss-20200930xxexx321.htm	Edgar Link	pending
goss-20200930xxexx322.htm	Edgar Link	pending
goss-20200930_cal.xml	Edgar Link	unprocessable
goss-20200930_def.xml	Edgar Link	unprocessable
goss-20200930_htm.xml	Edgar Link	completed
goss-20200930_lab.xml	Edgar Link	unprocessable
goss-20200930_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOSS
Gossamer Bio, Inc. Stock $goss

2020 Q4 Form 10-Q Financial Statement

#000172811720000009 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS Gossamer Bio, Inc. Stock $goss

2020 Q4 Form 10-Q Financial Statement

#000172811720000009 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS
Gossamer Bio, Inc. Stock $goss